Microbot Medical (NASDAQ:MBOT – Get Free Report) had its target price cut by equities research analysts at Citizens Jmp from $2.50 to $2.00 in a research report issued on Tuesday, Benzinga reports. The brokerage presently has a “market outperform” rating on the biotechnology company’s stock. Citizens Jmp‘s target price indicates a potential upside of 210.37% from the stock’s current price.
Other equities research analysts also recently issued reports about the stock. Zacks Research downgraded shares of Microbot Medical from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 20th. UBS Group set a $2.50 price target on Microbot Medical in a research note on Friday, October 23rd. B. Riley Financial assumed coverage on Microbot Medical in a report on Friday, September 11th. They issued a “buy” rating and a $4.00 price target on the stock. Weiss Ratings downgraded Microbot Medical from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, November 4th. Finally, Citigroup assumed coverage on Microbot Medical in a report on Friday, October 23rd. They set a “market outperform” rating for the company. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Microbot Medical presently has an average rating of “Moderate Buy” and a consensus target price of $5.00.
Check Out Our Latest Stock Report on MBOT
Microbot Medical Stock Down 34.2%
Shares of MBOT opened at $0.64 on Tuesday. Microbot Medical has a 52-week low of $0.52 and a 52-week high of $2.85. The company has a 50-day simple moving average of $1.15 and a 200-day simple moving average of $1.79. The company has a market capitalization of $43.28 million, a PE ratio of -2.48 and a beta of 1.07.
Microbot Medical (NASDAQ:MBOT – Get Free Report) last released its quarterly earnings data on Friday, November 13th. The biotechnology company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.01). The company had revenue of $0.07 million for the quarter, compared to analysts’ expectations of $0.01 million. On average, research analysts anticipate that Microbot Medical will post -0.30 EPS for the current year.
Institutional Trading of Microbot Medical
A number of large investors have recently made changes to their positions in the stock. CTC Alternative Strategies Ltd. purchased a new position in shares of Microbot Medical during the first quarter valued at approximately $28,000. Bank of America Corp DE grew its stake in Microbot Medical by 1,688.1% in the 1st quarter. Bank of America Corp DE now owns 75,799 shares of the biotechnology company’s stock worth $183,000 after acquiring an additional 71,560 shares during the period. Cetera Investment Advisers grew its stake in Microbot Medical by 44.7% in the 1st quarter. Cetera Investment Advisers now owns 42,412 shares of the biotechnology company’s stock worth $102,000 after acquiring an additional 13,099 shares during the period. Finally, Private Advisor Group LLC purchased a new stake in Microbot Medical in the 1st quarter worth approximately $54,000. Institutional investors and hedge funds own 16.30% of the company’s stock.
About Microbot Medical
Microbot Medical is a medical-device company developing robotic technologies for endovascular procedures. Its work focuses on tools intended to help physicians navigate blood vessels and perform minimally invasive interventions. The company’s lead platform, LIBERTY, is a remotely operated robotic system designed for endovascular procedures. The system is intended to work with guidewires and catheters and to support physicians in controlling these devices during treatment. Microbot Medical is based in the United States and has roots in Israel.
Further Reading
- Five stocks we like better than Microbot Medical
- Tyson Foods’ 10% Surge Puts a Breakout in Sight, But Wall Street Remains Cautious
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
Receive News & Ratings for Microbot Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical and related companies with MarketBeat.com's FREE daily email newsletter.
